AZ084

AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma[1]. AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer[1][2].

Product Specifications

CAS Number

[929300-19-6]

Product Name Alternative

Hydroxypropyl Cellulose, Viscosity(5%):75-150mPa.s, MW 100000,Hydroxypropyl Cellulose, Viscosity(1%):150-400mPa.s,Hydroxypropyl Cellulose, Viscosity(1%):1275-3500mPa.s,Hydroxypropyl Cellulose, Viscosity(1%):4000-6500mPa.s

UNSPSC

12352005

Target

CCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/az084.html

Purity

99.65

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(C1=NC=C(N)C=C1)N2CCC3(CCN(CC4=C5CC(C)(C)OC5=CC=C4)CC3)CC2

Molecular Formula

C26H34N4O2

Molecular Weight

434.57

References & Citations

[1]Connolly S, et al. Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration. Biochem Pharmacol. 2012 Mar 15;83 (6) :778-87.|[2]Wang M, et al. Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions. Cancer Immunol Immunother. 2022 Apr 15.